Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Fluoguide: FG001 shines again

CB

Christian Binder

Redeye comments on Fluoguide presenting clinical trial data from its phase I/II trial in aggressive brain cancer. We judge the presented data further strengthen evidence around FG001’s efficacy in this indication and bode well for the coming top-line data readout later this year. We increase our estimated LoA for FG001 in aggressive brain cancer and raise our Base Case.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers